Literature DB >> 12935294

Regulation of interleukin-3-induced substrate phosphorylation and cell survival by SHP-2 (Src-homology protein tyrosine phosphatase 2).

Helen Wheadon1, Christine Edmead, Melanie J Welham.   

Abstract

The cytosolic SHP-2 (Src homology protein tyrosine phosphatase 2) has previously been implicated in IL-3 (interleukin-3) signalling [Bone, Dechert, Jirik, Schrader and Welham (1997) J. Biol. Chem. 272, 14470 -14476; Craddock and Welham (1997) J. Biol. Chem. 272, 29281-29289; Welham, Dechert, Leslie, Jirik and Schrader (1994) J. Biol. Chem. 269, 23764-23768; Qu, Nguyen, Chen and Feng (2001) Blood 97, 911-914]. To investigate the role of SHP-2 in IL-3 signalling in greater detail, we have inducibly expressed WT (wild-type) or two potentially substrate-trapping mutant forms of SHP-2, generated by mutation of Asp-425 to Ala (D425A) or Cyst-459 to Ser (C459S), in IL-3-dependent BaF/3 cells. Effects on IL-3-induced tyrosine phosphorylation, signal transduction and functional responses were examined. Expression of C459S SHP-2 protected the beta-chain of the murine IL-3R (IL-3 receptor), the adaptor protein Gab2 (Grb2-associated binder 2), and a cytosolic protein of 48 kDa from tyrosine dephosphorylation, consistent with them being bona fide substrates of SHP-2 in IL-3 signalling. The tyrosine phosphorylation of a 135 kDa transmembrane protein was also protected upon expression of C459S SHP-2. We have identified the inhibitory immunoreceptor PECAM-1 (platelet endothelial cell adhesion molecule-1)/CD31 (cluster determinant 31) as a component of this 135 kDa substrate and also show that IL-3 can induce tyrosine phosphorylation of PECAM-1. Expression of WT, C459S and D425A forms of SHP-2 had little effect on IL-3-driven proliferation or STAT5 (signal transduction and activators of transcription) phosphorylation or activation of protein kinase B. However, expression of WT SHP-2 increased ERK (extracellular-signal-regulated kinase) activation. Interestingly, expression of C459S SHP-2 decreased ERK activation at later times after IL-3 stimulation, but potentiated IL-3-induced activation of Jun N-terminal kinases. In addition, expression of C459S SHP-2 decreased cell survival in suboptimal IL-3 and upon IL-3 withdrawal. These findings indicate that SHP-2 plays an important role in mediating the anti-apoptotic effect of IL-3 and raises the possibility that PECAM-1 participates in the modulation of cytokine-induced signals.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12935294      PMCID: PMC1223759          DOI: 10.1042/BJ20031160

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  73 in total

1.  Identification of Shp-2 as a Stat5A phosphatase.

Authors:  Yuhong Chen; Renren Wen; Shoua Yang; James Schuman; Eric E Zhang; Taolin Yi; Gen-Sheng Feng; Demin Wang
Journal:  J Biol Chem       Date:  2003-03-03       Impact factor: 5.157

2.  A role for JNK/SAPK in proliferation, but not apoptosis, of IL-3-dependent cells.

Authors:  A Smith; F Ramos-Morales; A Ashworth; M Collins
Journal:  Curr Biol       Date:  1997-11-01       Impact factor: 10.834

3.  Structural determinants of SHP-2 function and specificity in Xenopus mesoderm induction.

Authors:  A M O'Reilly; B G Neel
Journal:  Mol Cell Biol       Date:  1998-01       Impact factor: 4.272

4.  SHP1 and SHP2 protein-tyrosine phosphatases associate with betac after interleukin-3-induced receptor tyrosine phosphorylation. Identification of potential binding sites and substrates.

Authors:  H Bone; U Dechert; F Jirik; J W Schrader; M J Welham
Journal:  J Biol Chem       Date:  1997-05-30       Impact factor: 5.157

5.  Characterization of two SHP-2-associated binding proteins and potential substrates in hematopoietic cells.

Authors:  H Gu; J D Griffin; B G Neel
Journal:  J Biol Chem       Date:  1997-06-27       Impact factor: 5.157

6.  A deletion mutation in the SH2-N domain of Shp-2 severely suppresses hematopoietic cell development.

Authors:  C K Qu; Z Q Shi; R Shen; F Y Tsai; S H Orkin; G S Feng
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

7.  Abnormal mesoderm patterning in mouse embryos mutant for the SH2 tyrosine phosphatase Shp-2.

Authors:  T M Saxton; M Henkemeyer; S Gasca; R Shen; D J Rossi; F Shalaby; G S Feng; T Pawson
Journal:  EMBO J       Date:  1997-05-01       Impact factor: 11.598

8.  P110delta, a novel phosphoinositide 3-kinase in leukocytes.

Authors:  B Vanhaesebroeck; M J Welham; K Kotani; R Stein; P H Warne; M J Zvelebil; K Higashi; S Volinia; J Downward; M D Waterfield
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-29       Impact factor: 11.205

9.  Interleukin-3 induces association of the protein-tyrosine phosphatase SHP2 and phosphatidylinositol 3-kinase with a 100-kDa tyrosine-phosphorylated protein in hemopoietic cells.

Authors:  B L Craddock; M J Welham
Journal:  J Biol Chem       Date:  1997-11-14       Impact factor: 5.157

10.  Src homology 2 protein tyrosine phosphatase (SHPTP2)/Src homology 2 phosphatase 2 (SHP2) tyrosine phosphatase is a positive regulator of the interleukin 5 receptor signal transduction pathways leading to the prolongation of eosinophil survival.

Authors:  K Pazdrak; T Adachi; R Alam
Journal:  J Exp Med       Date:  1997-08-18       Impact factor: 14.307

View more
  7 in total

Review 1.  The Src homology 2 domain tyrosine phosphatases SHP-1 and SHP-2: diversified control of cell growth, inflammation, and injury.

Authors:  Z Z Chong; K Maiese
Journal:  Histol Histopathol       Date:  2007-11       Impact factor: 2.303

2.  Protein tyrosine phosphatase SHP2 regulates TGF-β1 production in airway epithelia and asthmatic airway remodeling in mice.

Authors:  X-J Qin; G-S Zhang; X Zhang; Z-W Qiu; P-L Wang; Y-W Li; W Li; Q-M Xie; Y-H Ke; J J Lee; H-H Shen
Journal:  Allergy       Date:  2012-10-11       Impact factor: 13.146

3.  Molecular mechanisms for enhancement of stromal cell-derived factor 1-induced chemotaxis by platelet endothelial cell adhesion molecule 1 (PECAM-1).

Authors:  Yoshihiro Umezawa; Hiroki Akiyama; Keigo Okada; Shinya Ishida; Ayako Nogami; Gaku Oshikawa; Tetsuya Kurosu; Osamu Miura
Journal:  J Biol Chem       Date:  2017-10-03       Impact factor: 5.157

4.  PECAM-1 is involved in BCR/ABL signaling and may downregulate imatinib-induced apoptosis of Philadelphia chromosome-positive leukemia cells.

Authors:  Nan Wu; Tetsuya Kurosu; Gaku Oshikawa; Toshikage Nagao; Osamu Miura
Journal:  Int J Oncol       Date:  2012-12-06       Impact factor: 5.650

5.  Subthreshold IKK activation modulates the effector functions of primary mast cells and allows specific targeting of transformed mast cells.

Authors:  Sebastian Drube; Franziska Weber; Romy Loschinski; Mandy Beyer; Mandy Rothe; Anja Rabenhorst; Christiane Göpfert; Isabel Meininger; Michaela A Diamanti; David Stegner; Norman Häfner; Martin Böttcher; Kirstin Reinecke; Thomas Herdegen; Florian R Greten; Bernhard Nieswandt; Karin Hartmann; Oliver H Krämer; Thomas Kamradt
Journal:  Oncotarget       Date:  2015-03-10

6.  TAK1 and IKK2, novel mediators of SCF-induced signaling and potential targets for c-Kit-driven diseases.

Authors:  Sebastian Drube; Franziska Weber; Christiane Göpfert; Romy Loschinski; Mandy Rothe; Franziska Boelke; Michaela A Diamanti; Tobias Löhn; Julia Ruth; Dagmar Schütz; Norman Häfner; Florian R Greten; Ralf Stumm; Karin Hartmann; Oliver H Krämer; Anne Dudeck; Thomas Kamradt
Journal:  Oncotarget       Date:  2015-10-06

Review 7.  SHP-2 in Lymphocytes' Cytokine and Inhibitory Receptor Signaling.

Authors:  Charlène Niogret; Walter Birchmeier; Greta Guarda
Journal:  Front Immunol       Date:  2019-10-25       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.